Author:
Resende Carlos Ananias Aparecido,Ribeiro Anna Júlia,Gandra Isadora Braga,Silva Kamila Alves,Lopes Lucas da Silva,Barcelos Isabelle Caroline dos Santos,Couto Carolina Alves Petit,de Faria Mariana Teixeira,Pereira Sabrina Paula,Xavier Sandra Rodrigues,Machado Juliana Martins,da Paz Mariana Campos,Chaves Ana Thereza,Coelho Eduardo Antônio Ferraz,Giunchetti Rodolfo Cordeiro,Chávez-Fumagalli Miguel Angel,Dutra Walderez Ornelas,Gonçalves Ana Alice Maia,Galdino Alexsandro Sobreira
Abstract
Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is an important public health problem, occurring mainly in Latin America. The disease has a major social and economical effect, negatively impacting the life of the infected individuals, and bringing great costs to public health. An early and accurate diagnosis is essential for administration of early treatment. In addition, prognostic tests may aid disease management, decreasing hospitalization costs. However, the serological diagnostic scenario for CD still faces several challenges, making the development of new diagnostic kits a pressing matter. Facing this scenario, several researchers have expanded efforts in developing and testing new antigens, such as recombinant proteins and recombinant multiepitope proteins, with promising results. These recombinant antigens offer several advantages, such as improved sensitivity and specificity, in addition to facilitated scaling. Also, it has been possible to observe a rising number of studies using ELISA and point-of-care platforms, employing these antigens in the past few years. Among them, recombinant proteins were the most applied antigens, demonstrating great capacity to discriminate between positive and negative samples. Although fewer in number, recombinant multiepitope proteins also demonstrated an improved diagnostic performance. Indeed, a great number of studies employing these antigens showed sensitivity and specificity values above 90%, greatly impacting diagnostic accuracy. Nevertheless, despite the good results found, it is still possible to observe some bottlenecks in the development of new antigens, such as the scarcity of tests with sera from the acute phase and the variability of results in different geographic areas. In this sense, aiming to contribute to control and health programs, the continuous search for a more accurate serological diagnosis is essential, both for the acute and chronic phases of the disease.